此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

靶向CMV抗原的PEP-CMV疫苗治疗初诊小儿HGG和DIPG及复发性髓母细胞瘤

2026年11月16日 更新者:Nationwide Children's Hospital

针对 CMV 抗原的新型肽疫苗 (PEP-CMV) 的 2 期试验用于新诊断的小儿高级别胶质瘤和弥漫性脑桥胶质瘤和复发性髓母细胞瘤

This study will address the question of whether targeting CMV antigens with PEP-CMV can serve as a novel immunotherapeutic approach in pediatric patients with newly-diagnosed high-grade glioma (HGG) or diffuse intrinsic pontine glioma (DIPG) as well as recurrent medulloblastoma (MB).

PEP-CMV is a vaccine mixture of a peptide referred to as Component A. Component A is a synthetic long peptide (SLP) of 26 amino acid residues from human pp65. The SLPs encode multiple potential class I, class II, and antibody epitopes across several haplotypes. Component A will be administered as a stable water:oil emulsion in Montanide ISA 51.

Funding Source - FDA OOPD

研究概览

详细说明

This phase II clinical trial will have 3 strata in order to assess the efficacy of a highly immunogenic CMV-directed peptide vaccines in children with (1) recurrent medulloblastoma (rMB), (2) newly-diagnosed high-grade gliomas (HGG) and (3) newly-diagnosed diffuse intrinsic pontine glioma (DIPG). Each stratum will run independently with a different endpoint and statistical design.

Within each stratum, the populations that may be used for analysis are defined as:

  • Safety Analysis: Patients who receive at least 1 dose of the treatment will be used for safety analyses.
  • Efficacy Analysis: Patients who receive at least 1 dose of the treatment will be used for efficacy analyses.

Stratum I: Patients with recurrent medulloblastoma with measurable disease (see eligibility) can be enrolled at any point following recurrence regardless of any prior therapy. For the purpose of this study, recurrence will be defined as a new lesion confirmed by biopsy or resection, positive cerebrospinal fluid (CSF) cytology, or recurrent/progressive tumor on MRI.

Strata II [CLOSED on 19Aug2026] and III: Patients with newly-diagnosed high-grade glioma [CLOSED on 19Aug2026] or DIPG may be enrolled any time within 42 days after completing radiation.

Cycle 1 (Induction cycle) is 77±2 days. Patients will receive one course of temozolomide 200 mg/m2/day x 5 days on Days 1-5 of cycle 1 and receive PEP-CMV vaccine intradermally at dose level 1 (250 μg/m2 ) on Days 21, 35 ±2 days, and 49 ±2 days. After the induction cycle which is 77 ± 2 days, each subsequent cycle is 28 days. Starting in cycle 2, PEP-CMV vaccine is administered intradermally every 28 days on day 1 of each course. Patient can continue to receive PEP-CMV every 28 days for a total of 24 cycles.

Patients will receive a tetanus (Td) booster (Td 5 flocculation units, Lf) at the time of enrollment. Immunotherapy begins with a Td pre-conditioning vaccine (Td 1 Lf, in 0.4 mL of saline) delivered i.d. at the RIGHT groin site of the vaccine injection 6-24 hours prior to the first vaccine on day 21.

The PEP-CMV vaccine will be administered as follows: 250 µg/m2 (up to a maximum of 500 µg) of Component A mixed with Montanide ISA-51 (1:1 volume ratio) intradermally administered half in the RIGHT groin and half in the LEFT groin.

研究类型

介入性

注册 (估计的)

120

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Colorado
      • Aurora、Colorado、美国、80045
        • 招聘中
        • Children's Hospital Colorado
        • 接触:
        • 首席研究员:
          • Holly Lindsay, MD
    • District of Columbia
      • Washington D.C.、District of Columbia、美国、20010
        • 招聘中
        • Children's National Medical Center
        • 接触:
        • 首席研究员:
          • Eugene Hwang
    • Florida
      • Miami、Florida、美国、33155
    • Illinois
      • Chicago、Illinois、美国、60611
        • 尚未招聘
        • Ann & Robert H. Lurie Children's Hospital of Chicago
        • 首席研究员:
          • Ashley Plant, MD
        • 接触:
    • Massachusetts
      • Boston、Massachusetts、美国、02215
        • 尚未招聘
        • Dana-Farber Cancer Institute
        • 首席研究员:
          • Karen Wright, MD
        • 接触:
    • Michigan
      • Ann Arbor、Michigan、美国、48109
        • 招聘中
        • C.S. Mott Children's Hospital
        • 接触:
    • Missouri
      • St Louis、Missouri、美国、63110
    • North Carolina
      • Durham、North Carolina、美国、27710
        • 招聘中
        • Duke Cancer Center
        • 首席研究员:
          • Daniel Landi, MD
        • 接触:
    • Ohio
      • Cincinnati、Ohio、美国、45229
        • 招聘中
        • Cincinnati Children's Hospital Medical Center
        • 首席研究员:
          • Peter de Blank, MD
        • 接触:
      • Columbus、Ohio、美国、43205
    • Pennsylvania
      • Philadelphia、Pennsylvania、美国、19104
        • 尚未招聘
        • Children's Hospital of Philadelphia
        • 接触:
        • 首席研究员:
          • Michael J Fisher, MD
    • Texas
      • Houston、Texas、美国、77030
        • 招聘中
        • Texas Children's Hospital
        • 接触:
        • 首席研究员:
          • Patricia Baxter, MD
    • Washington
      • Seattle、Washington、美国、98105
        • 招聘中
        • Seattle Children's Hospital
        • 接触:
        • 首席研究员:
          • Sarah Leary, MD

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

3年 至 39年 (孩子、成人)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria for patients with recurrent /progressive medulloblastoma (stratum I)

  1. Age: Patients must be ≥3 and ≤39 years of age at the time of study enrollment

  2. Diagnosis: Patients must have a diagnosis of medulloblastoma that is recurrent, progressive or refractory. All patients must have histological verification of a medulloblastoma, at original diagnosis or relapse.

    • Patients must have measurable disease defined as a lesion that can be measured in two perpendicular diameters on MRI.

  3. Metastatic Disease: Patients with M+ disease are eligible.

  4. Performance Status:

    Karnofsky ≥ 50% for patients >16 years of age or Lansky ≥ 50 for patients ≤ 16 years of age. Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.

  5. Prior Therapy:

    1. Radiotherapy: prior radiotherapy requirements Patients must have received prior disease-directed therapy including radiotherapy for their diagnosis of medulloblastoma unless patients are less than 4 years of age at the time of enrollment.

      For those less than 4 years of age at the time of enrollment, prior disease directed therapy does not have to include prior radiotherapy.

      Patients must have had their last fraction of:

      • Craniospinal irradiation, total body irradiation or radiation to ≥ 50% of pelvis > 3 months prior to enrollment.
      • Focal irradiation > 4 weeks prior to enrollment
    2. Myelosuppressive anticancer therapy: Patients must have received their last dose of myelosuppressive anticancer therapy at least 21 days prior to enrollment

    3. Immunotherapy: Patients must have received their last dose of any immunotherapy agents at least 30 days prior to enrollment

    4. Non-myelosuppressive anticancer agents: Patients must have received their last dose of non-myelosuppressive anticancer agents at least 7 days prior to study enrollment.

    5. Antibodies: Patients must have received their last dose of any antibodies at least 21 days prior to enrollment.

    6. Hematopoietic growth factors: Patients must have received their last dose of hematopoietic growth factors at least 14 days prior to enrollment for a long-acting growth factor (e.g. pegfilgrastim) or 7 days prior to enrollment for short-acting growth factor.

    7. Autologous stem cell infusion: At least 90 days must have elapsed after an autologous stem cell infusion

  6. Organ Function Requirements:

    1. Adequate bone marrow function defined as:

      • ANC (Absolute neutrophil count) ≥ 1000/µl.
      • Platelets ≥ 100,000/µl. (may be supported)
      • Hemoglobin > 8 g/dL. (may be supported)
    2. Adequate Renal Function defined as: Creatinine clearance or radioisotope GFR ≥ 70ml/min/1.73 m2 or A serum creatinine based on age/gender as follows:

      Age: Maximum Serum Creatinine (mg/dL)

      • 2 to < 6 years: 0.8 (Male) 0.8 (Female)
      • 6 to < 10 years: 1 (Male) 1 (Female)
      • 10 to < 13 years: 1.2 (Male) 1.2 (Female)
      • 13 to < 16 years: 1.5 (Male) 1.4 (Female)
      • ≥ 16 years: 1.7 (Male) 1.4 (Female)
    3. Adequate Liver Function Defined as

      • Total bilirubin ≤1.5 times institutional ULN
      • AST(SGOT) ≤3 × institutional upper limit of normal
      • ALT(SGPT) ≤3 × institutional upper limit of normal
    4. Adequate Neurological Function Defined as

      • Patients with neurological deficits should have deficits that are stable for a minimum of 2 weeks prior to enrollment.
      • Patients with current seizure disorders may be enrolled if seizures are well- controlled on antiepileptic therapies.
    5. Patients of childbearing or child-fathering potential must be willing to use a medically acceptable form of birth control, which includes abstinence, while being treated on this study and for three months after drug cessation.

    6. Signed informed consent according to institutional guidelines must be obtained prior to enrollment.

Inclusion Criteria for Patients with Newly-Diagnosed High-Grade Gliomas (HGG) (stratum II, CLOSED on 19Aug2026) and Newly-Diagnosed (DIPG) (stratum III)

  1. Age: Patients must be ≥3 and ≤39 years of age at the time of study enrollment

  2. Diagnosis

    1. Stratum II [CLOSED on 19Aug2026]: patients must have histologically confirmed, newly-diagnosed HGG (such as anaplastic astrocytoma, glioblastoma, H3K27-altered DMG).

      • Patients with a newly-diagnosed HGG must enroll within 6 weeks of their final dose of standard radiation therapy with or without chemotherapy.
      • Patients with primary spinal cord tumors are eligible
    2. Stratum III: Patients with a newly-diagnosed DIPG:

      • Patients with a radiographically typical DIPG, defined as a tumor with a pontine epicenter and diffuse involvement of more than 2/3 of the pons, are eligible without histologic confirmation.
      • Patients with brainstem lesions that do not meet these radiographic criteria will be eligible if there is histologic confirmation of an infiltrating astrocytoma WHO grades II-IV.
  3. Metastatic Disease: Patients with M+ disease are eligible.

  4. Performance Status:

    Karnofsky ≥ 50 for patients > 16 years of age and Lansky ≥ 50 for patients ≤ 16 years of age (See Appendix I). Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.

  5. Prior Therapy requirements: Patients must have received no prior therapy other than surgery, radiation, chemotherapy during radiotherapy and/or steroids (dexamethasone with goal to wean dexamethasone throughout protocol therapy).

    Patients with a newly diagnosed high-grade glioma or DIPG must enroll within 6 weeks of their final dose of standard of care radiation therapy with or without chemotherapy.

    1. Patients with HGG or DIPG are permitted, but not required, to have received chemotherapy during radiation. Bevacizumab is permitted prior to enrollment in patients with DIPG or HGG. Patients must have received their last dose of bevacizumab at least 14 days prior to enrollment.
    2. For HGG patients, Patients must have received radiotherapy at a standard dose of 54-59.4 Gy in 1.8 Gy fractions for approximately 6 weeks with an acceptable variance of 10%. Radiation therapy must have begun no later than 42 days after the date definitive surgery.
    3. For patients with DIPG, Patients must have received radiotherapy at a standard dose of radiotherapy of 54 Gy in 1.8 Gy daily fractions for approximately 6 weeks with an acceptable variance rate of 10%. Radiation therapy must have begun no later than 42 days after the date of radiographic diagnosis or biopsy
    4. For patients with spinal cord HGG: Patients must have received radiotherapy at a standard dose of 45-54 Gy in 1.8 Gy fractions for approximately 6-7 weeks with an acceptable variance of 10%
    5. For patients with metastatic disease: Patients may have received standard dose CSI
  6. Organ Function Requirements:

    1. Adequate bone marrow function defined as • ANC (Absolute neutrophil count) ≥ 1000/µl.

      • Platelets ≥ 100,000/µl. (may be supported)

      • Hemoglobin > 8 g/dL. (may be supported)

    2. Adequate Renal Function defined as: Creatinine clearance or radioisotope GFR ≥ 70ml/min/1.73 m2 or A serum creatinine based on age/gender as follows:

      Age: Maximum Serum Creatinine (mg/dL)

      • 2 to < 6 years: 0.8 (Male) 0.8 (Female)

      • 6 to < 10 years: 1 (Male) 1 (Female)

      • 10 to < 13 years: 1.2 (Male) 1.2 (Female)

      • 13 to < 16 years: 1.5 (Male) 1.4 (Female)

      • ≥ 16 years: 1.7 (Male) 1.4 (Female)

    3. Adequate Liver Function Defined as:

      • Total bilirubin ≤1.5 times institutional ULN

      • AST(SGOT) ≤3 × institutional upper limit of normal
      • ALT(SGPT) ≤3 × institutional upper limit of normal
    4. Adequate Neurological Function Defined as:

Patients with neurological deficits should have deficits that are stable for a minimum of 1 week prior to enrollment.

d. Patients of childbearing or child-fathering potential must be willing to use a medically acceptable form of birth control, which includes abstinence, while being treated on this study.

e. Signed informed consent according to institutional guidelines must be obtained prior to registration and for 3 months after drug cessation.

Exclusion Criteria for all strata:

  1. Pregnancy or Breast-Feeding:

    1. Pregnant or breast-feeding women will not be entered on this study due to known or unknown risks of fetal and teratogenic adverse events as seen in animal/human studies. Pregnancy tests must be obtained in girls who are post-monarchal. Males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method.
    2. Pregnancy Prevention Patients of childbearing or child fathering potential must be willing to use a medically acceptable form of birth control, which includes abstinence, while being treated on this study and for 3 months after drug cessation.
  2. Study Specific:

    1. Active infection requiring treatment
    2. Patients with malignancy related to HIV or solid organ transplant: known history of HIV, HBV surface antigen positivity or positive HCV antibody are not eligible. Viral testing is not required unless clinically indicated in patients without a known history
    3. Known immunosuppressive disease
    4. Patients with active renal, cardiac (congestive cardiac failure, myocardial infarction, myocarditis), or moderate to severe pulmonary problems generally defined by need for medical intervention (e.g., oxygen, medications) and/or limiting activities of daily living (generally CTCAE Grade 2 or higher) or shortness of breath with limited exertion are not eligible. Pulmonary conditions include (but are not limited to) COPD, asthma, and hemi-pneumectomy
    5. Patients receiving concomitant immunosuppressive agents for medical conditions; inhaled corticosteroids for asthma are allowed.
    6. Patients receiving concomitant tumor-directed therapy
    7. Patients receiving any other investigational drug therapy.
    8. Patients on dexamethasone > 0.1 mg/Kg/day up to maximum dose of 4 mg/day or equivalent.
    9. Patients with any clinically significant unrelated systemic illness (serious infections or significant cardiac, pulmonary, hepatic or other organ dysfunction).
    10. Patients with inability to return for follow-up visits or obtain follow-up studies required to assess toxicity to therapy
    11. Patients at high risk for imminent neurologic decline due to extensive bulk disease, midline shift, or herniation on MRI. These patients should be discussed with the study chairs.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:PEP-CMV

Participants will receive standard chemotherapy with temozolomide for five days, followed by the study vaccine, PEP-CMV, on day 21. Participants will receive a tetanus diphtheria (Td) booster vaccine and a small dose Td preconditioning vaccine to prepare their immune system to receive their first PEP-CMV vaccine. Participants will receive the first 3 PEP-CMV vaccines every 2 weeks, and after the third vaccine, the rest of the vaccines will be given monthly. The first cycle is 77 days and all subsequent cycles are 28 days. The PEP-CMV vaccine may be received for up to 24 cycles.

The PEP-CMV vaccine will be administered as follows: 250 µg/m2 (up to a maximum of 500 µg) of Component A mixed with Montanide ISA-51 (1:1 volume ratio) intradermally administered half in the RIGHT groin and half in the LEFT groin.

Patients will receive one course of temozolomide 200 mg/m2/day x 5 days on Days 1-5 of cycle 1

其他名称:
  • TMZ

Patients will receive a tetanus (Td) booster (Td 5 flocculation units, Lf) at the time of enrollment. Immunotherapy begins with a Td pre-conditioning vaccine (Td 1 Lf, in 0.4 mL of saline) delivered i.d. at the RIGHT groin site of the vaccine injection 6-24 hours prior to the first vaccine on day 21.

其他名称:
  • 时差

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
4-mo PFS in patients with recurrent medulloblastoma
大体时间:4 months

To determine the progression-free survival (PFS) at 4 months in pediatric or young adult patients with recurrent medulloblastoma treated with PEP-CMV.

4 months
1-yr OS in patients with newly diagnosed DIPG
大体时间:one year

To estimate the 1-year Overall Survival (OS) distribution in patients with newly diagnosed DIPG treated with radiotherapy followed by PEP-CMV

one year
1-yr PFS in patients with newly diagnosed HGG
大体时间:one year

To estimate the 1-year Progression Free Survival (PFS) distribution in patients with newly diagnosed HGG treated with radiotherapy followed by PEP-CMV

one year

次要结果测量

结果测量
措施说明
大体时间
ORR in patients with recurrent medulloblastoma
大体时间:From Day 1 of treatment through 30 days following end of protocol treatment

To determine the objective response rate (ORR) = partial response (PR) + complete response (CR) in patients with recurrent medulloblastoma treated with PEP-CMV

From Day 1 of treatment through 30 days following end of protocol treatment
PFS in patients with recurrent medulloblastoma
大体时间:one year

To determine the 1-year Progression Free Survival (PFS) in patients with recurrent Medulloblastoma treated with PEP-CMV.

one year
OS in patients with newly diagnosed HGG by PEP-CMV
大体时间:2 years

To determine the 2-year Overall Survival (OS) in patients newly diagnosed with HGG treated with PEP-CMV.

2 years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

合作者

调查人员

  • 首席研究员:Maryam Fouladi, MD、Nationwide Children's Hospital
  • 学习椅:Daniel Landi, MD、Duke Cancer Center
  • 学习椅:Eric M Thompson, MD、Washington University - St. Louis Children's Hospital

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2024年7月18日

初级完成 (估计的)

2028年6月15日

研究完成 (估计的)

2030年6月15日

研究注册日期

首次提交

2021年10月15日

首先提交符合 QC 标准的

2021年10月15日

首次发布 (实际的)

2021年10月27日

研究记录更新

最后更新发布 (实际的)

2026年11月19日

上次提交的符合 QC 标准的更新

2026年11月16日

最后验证

2026年11月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅